drugset
drugset / Trial / NCT03896854

CART-19 T Cell in CD19 Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT03896854 ↗

Phase 1/2 Unknown 15 enrolled Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of targeted CD19 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CD19 positive relapsed or refractory acute myeloid leukemia.

Timeline

Start
2017-10-18
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Tisagenlecleucel Cell therapy 1e+06 cells/kg Intravenous
Subject Tisagenlecleucel Cell therapy 2e+07 cells/kg Intravenous

Indications

acute myeloid leukemia